clinical trial · NCT05648591
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
SchizophreniaBipolar I DisorderIloperidone
brief summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
started
May 24, 2023
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Oct 1, 2026
official title
Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol